Clinical trials: Immunoglobulin
Thyroid Eye Disease
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
- Trial name
- NCT05524571
- Testing
- Batoclimab
- Where
- 45 sites in United States, Australia and 9 more
- Volunteers
- 86 people
- Sponsor
- Immunovant Sciences GmbH
Viremia, Bacteremia
Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections
The goal of this clinical trial is to learn about the benefit of IVIG in donor-derived infections and the potential immunomodulatory effect on transplanted organs. The main questions it aims to answer are: 1.
- Conditions
- Viremia, Bacteremia, Acute Rejection of Renal Transplant
- Trial name
- NCT05799716
- Testing
- IVIG
- Volunteers
- 40 people
- Sponsor
- Shanghai Changzheng Hospital
Neuroblastoma
Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
RATIONALE: Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy.
- Trial name
- NCT00030719
- Testing
- filgrastim, monoclonal antibody Ch14.18, busulfan
- Where
- 32 sites in Austria, Belgium and 11 more
- Volunteers
- 175 people
- Sponsor
- University of Leicester
Cancer, Neoplasm Metastasis
Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors
This study is being performed to evaluate the safety and tolerability of the TRC093 antibody.
- Trial name
- NCT00492830
- Testing
- TRC093 recombinant humanized IgG1k monoclonal antibody
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Healthy
3Sm Challenge Model Protocol
The 3Sm challenge study is a small clinical study in eight healthy volunteers who will be injected with a protein which includes a short portion ('3Sm peptide') which is derived from a part (the '3S region') of the coat protein…
- Trial name
- NCT04753892
- Testing
- 3SM2-G-CRM197 with squalene adjuvant
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Chronic Lymphocytic Leukemia
HuMax-CD20 in Chronic Lymphocytic Leukemia
The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Chronic Lymphocytic Leukemia.
- Trial name
- NCT00093314
- Testing
- HuMax-CD20
- Where
- United States
- Sponsor
- GlaxoSmithKline
Toxic Shock Syndrome
Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study
Staphylococcus aureus and Streptococcus pyogenes produce many virulence factors. Some of them are responsible for severe infections in humans. Superantigen toxins synthesized by S. aureus or by S.
- Trial name
- IVIG (NCT02219165)
- Testing
- Intravenous human immunoglobulin, Albumin
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Chronic Primary Immune Thrombocytopenia (ITP)
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP
- Trial name
- ITP (NCT07059000)
- Testing
- Kedrion IVIG 10%
- Where
- 28 sites in United States, Czechia and 6 more
- Volunteers
- 40 people
- Sponsor
- Kedrion S.p.A.
HER2 + Breast Cancer
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
The study is being conducted to evaluate the clinical efficacy of HLX87 in combination with HLX22 or pertuzumab vs. TCbHP in the neoadjuvant therapy of HER2-positive early or locally advanced breast cancer.
- Trial name
- NCT07294534
- Testing
- HLX87+HX22, HLX87 + Pertuzumab, TCbHP
- Volunteers
- 817 people
- Sponsor
- Shanghai Henlius Biotech
COVID
Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2
Trial design. Randomized, double-blind, placebo-controlled trial in a catchment population of 2,020,860 age-appropriate subjects in the state of Buenos Aires and 235,000 in the city of Buenos Aires. Institutions.
- Trial name
- NCT04479163
- Testing
- Convalescent Plasma
- Where
- 11 sites in Argentina
- Volunteers
- 165 people
- Sponsor
- Fundacion Infant
Covid-19, IgG Antibody
Correlation Analysis of Covid-19 IgG Antibody Level in Seminal Plasma and Semen Index
Since December 2019, more and more cases of unexplained pneumonia appeared after exposure to the South China Seafood Market in Wuhan City, Hubei Province.
- Conditions
- Covid-19, IgG Antibody, Semen Index
- Trial name
- NCT05212506
- Testing
- vaccinated and unvaccinated
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Shanghai First Maternity and Infant Hospital
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
This is a single-arm, open label, multicenter Phase 1/2 study evaluating ALLO-501A in adult subjects with R/R LBCL and CLL/SLL. The purpose of the ALPHA2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in…
- Trial name
- ALPHA2 (NCT04416984)
- Testing
- ALLO-501A, ALLO-647, Fludarabine
- Where
- 29 sites in United States, Australia and 1 more
- Volunteers
- 160 people
- Sponsor
- Allogene Therapeutics
Advanced Solid Tumors
A Study of MRG003 in Patients With Advanced Solid Tumors
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG003, as well as immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG003 in patients with advanced solid tumors…
- Trial name
- NCT04868344
- Testing
- MRG003
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants…
- Trial name
- NCT07680764
- Testing
- Pumitamig, Imzokitug, Pemetrexed
- Where
- 74 sites in United States, Argentina and 10 more
- Volunteers
- 160 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer Metastatic
MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer
The primary goal of this study is to characterize the safety, tolerability, and maximum tolerated dose (MTD) of MGD007 when combined with MGA012.
- Trial name
- NCT03531632
- Testing
- MGD007 + MGA012
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- MacroGenics
Passive Transmission of Maternal and Infant Antibodies
Passive Transmission of COVID-19 Antibody From Mother to Infant
At present, there is no relevant research focusing on children's acquisition of novel coronavirus antibodies through maternal passive transmission.
- Trial name
- NCT05851911
- Testing
- sars-cov-2 vaccine or infection
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Chongqing Medical University
Solid Tumors, Gastric Cancer
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study.
- Conditions
- Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
- Trial name
- NCT06710132
- Testing
- M9140
- Where
- 81 sites in United States, Australia and 8 more
- Volunteers
- 184 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Solid Tumor
Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors
An exploratory study to evaluate for the treatment of advanced solid tumors that failed standard treatments.
- Trial name
- NCT04569916
- Testing
- radiotherapy, irinotecan liposome, apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Antibody-mediated Rejection
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
The purpose of this study is to assess the safety, tolerability, and efficacy of efgartigimod PH20 SC given by a prefilled syringe in participants with Antibody-Mediated Rejection (AMR) after kidney transplantation.
- Trial name
- Shamrock (NCT06503731)
- Testing
- Efgartigimod PH20 SC - prefilled syringe
- Where
- 23 sites in United States, Austria and 6 more
- Volunteers
- 33 people
- Sponsor
- argenx
Granulomatosis With Polyangiitis (Wegener's)
Assessing Granulomatosis With Polyangiitis Activity: 18F-FDG PET/CT vs BVAS v3
The goal of this observational study is to quantify activity and extent of disease in patients with GPA using 18F-FDG PET/CT. The main questions it aims to answer are: Sensitivity of 18 F-FDG PET/CT in patients with GPA?…
- Trial name
- NCT07712172
- Testing
- 18F-FDG, 18F-FDG PET/CT
- Where
- India
- Volunteers
- 31 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.